KROS
Keros Therapeutics Inc
$
16.200
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.750
Open
16.240
VWAP
16.17
Vol
1.33M
Mkt Cap
493.55M
Low
15.890
Amount
21.47M
EV/EBITDA(TTM)
-4.44
Total Shares
36.08M
EV
-199.92M
EV/OCF(TTM)
-2.25
P/S(TTM)
2.67
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.58M
+17.52%
-0.160
-85.96%
616.25K
-99.71%
-0.925
-125.55%
622.50K
-96.57%
-0.960
+26.32%
Estimates Revision
The market is revising No Change the revenue expectations for Keros Therapeutics, Inc. (KROS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 21.35%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+21.35%
In Past 3 Month
8 Analyst Rating
40.93% Upside
Wall Street analysts forecast KROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 22.83 USD with a low forecast of 15.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
4 Hold
0 Sell
Moderate Buy
40.93% Upside
Current: 16.200
Low
15.00
Averages
22.83
High
35.00
40.93% Upside
Current: 16.200
Low
15.00
Averages
22.83
High
35.00
Oppenheimer
Andreas Argyrides
Outperform
maintain
$23 -> $27
2025-11-07
New
Reason
Oppenheimer
Andreas Argyrides
Price Target
$23 -> $27
2025-11-07
New
maintain
Outperform
Reason
Oppenheimer analyst Andreas Argyrides raised the firm's price target on Keros Therapeutics to $27 from $23 and keeps an Outperform rating on the shares following quarterly results. The firm continues to anticipate the Phase 2 trial initiation for KER-065/DMD in Q1 2026, and is encouraged by recent additional Phase 1 data demonstrating continued durability and safe profile. As such, Oppenheimer sees KER-065 as a potentially differentiated TGF-beta inhibitor by avoiding BMP9/10 binding with no SAEs, and see broader potential across other bone disorders.
BofA
Jason Zemansky
Buy -> Neutral
downgrade
$32 -> $18
2025-06-10
Reason
BofA
Jason Zemansky
Price Target
$32 -> $18
2025-06-10
downgrade
Buy -> Neutral
Reason
BofA
Jason Zemansky
Buy
maintain
$33 -> $32
2025-05-27
Reason
BofA
Jason Zemansky
Price Target
$33 -> $32
2025-05-27
maintain
Buy
Reason
Scotiabank
Outperform
to
NULL
downgrade
$41 -> $26
2025-05-12
Reason
Scotiabank
Price Target
$41 -> $26
2025-05-12
downgrade
Outperform
to
NULL
Reason
Scotiabank lowered the firm's price target on Keros Therapeutics to $26 from $41 and keeps an Outperform rating on the shares. The firm is updating its price targets on biotechnology stocks following Q1 results, the analyst tells investors. The firm sees limited value-driving catalysts for the stock in the near-term.
H.C. Wainwright
Andrew Fein
Buy
downgrade
$40 -> $25
2025-05-08
Reason
H.C. Wainwright
Andrew Fein
Price Target
$40 -> $25
2025-05-08
downgrade
Buy
Reason
Truist Securities
Srikripa Devarakonda
Strong Buy
Maintains
$43 → $25
2025-04-09
Reason
Truist Securities
Srikripa Devarakonda
Price Target
$43 → $25
2025-04-09
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Keros Therapeutics to $25 from $43 and keeps a Buy rating on the shares as part of a broader research note on Biotech. Keros is an attractive company for investors with a longer-term horizon, particularly in the context of the current macro environment and uncertainty around Biopharma, and the stock is trading below cash, the analyst tells investors in a research note. The stock is undervalued with no value to any pipeline programs or even the partnered ones, though the firm is acknowledging investor skepticism given safety concerns, Truist adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Keros Therapeutics Inc (KROS.O) is -5.38, compared to its 5-year average forward P/E of -10.36. For a more detailed relative valuation and DCF analysis to assess Keros Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-10.36
Current PE
-5.38
Overvalued PE
-4.40
Undervalued PE
-16.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.54
Current EV/EBITDA
1.87
Overvalued EV/EBITDA
1.30
Undervalued EV/EBITDA
-6.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
17444.29
Current PS
16.20
Overvalued PS
87667.81
Undervalued PS
-52779.22
Financials
Annual
Quarterly
FY2025Q3
YoY :
+3575.77%
14.26M
Total Revenue
FY2025Q3
YoY :
-73.77%
-15.38M
Operating Profit
FY2025Q3
YoY :
-86.25%
-7.28M
Net Income after Tax
FY2025Q3
YoY :
-87.23%
-0.18
EPS - Diluted
FY2025Q3
YoY :
-110.09%
3.12M
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
-100.16%
35.30
FCF Margin - %
FY2025Q3
YoY :
-99.63%
-51.04
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
180.6M
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
9.5M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
390.9K
Volume
1
0-12
Months
980.9K
Volume
4
Bought
0-3
0
0.0
Volume
Months
3-6
1
2.6M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
6
1.9M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
180.6M
USD
2
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
9.5M
USD
Months
0-12
0
0.0
USD
Months
KROS News & Events
Events Timeline
2025-11-05 (ET)
2025-11-05
16:05:25
Keros Therapeutics Announces Q3 Earnings Per Share of 18 Cents, Below Consensus Estimate of 92 Cents
2025-10-20 (ET)
2025-10-20
06:05:46
Keros Therapeutics Plans to Buy Back $194.4 Million in Shares
2025-10-15 (ET)
2025-10-15
06:37:52
Keros Therapeutics reveals plan for share buyback program
Sign Up For More Events
Sign Up For More Events
News
8.0
10-20NewsfilterKeros Therapeutics Launches Tender Offer to Buy Back Up to $194.4 Million in Shares
8.0
10-20SeekingAlphaKeros Therapeutics Launches Tender Offer to Buy Back Up to $194.4 Million in Shares
9.0
08-21NewsfilterADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal
Sign Up For More News
People Also Watch
FC
Franklin Covey Co
14.890
USD
-6.35%
SVC
Service Properties Trust
2.000
USD
-2.44%
ALNT
Allient Inc
52.260
USD
+3.44%
VBNK
Versabank
11.650
USD
-0.77%
URGN
Urogen Pharma Ltd
23.240
USD
-1.27%
ESPR
Esperion Therapeutics Inc
2.660
USD
+6.40%
BIOX
Bioceres Crop Solutions Corp
1.790
USD
+7.83%
API
Agora Inc
3.490
USD
+0.58%
MYE
Myers Industries Inc
17.440
USD
-0.40%
FAQ
What is Keros Therapeutics Inc (KROS) stock price today?
The current price of KROS is 16.2 USD — it has increased 0.19 % in the last trading day.
What is Keros Therapeutics Inc (KROS)'s business?
What is the price predicton of KROS Stock?
What is Keros Therapeutics Inc (KROS)'s revenue for the last quarter?
What is Keros Therapeutics Inc (KROS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Keros Therapeutics Inc (KROS)'s fundamentals?
How many employees does Keros Therapeutics Inc (KROS). have?